According to our findings, serum prolactin levels in prolactinoma before and after the cabergoline treatment were significantly different (128.0±99.7 vs 35.5±39.5 ng/ml, p=0.0001, respectively). Mean cumulative cabergoline dose were calculated as 218.1±252.5 mg. We found that the mean pre-treatment MPV values in prolactinoma group were lower than post-treatment MPV values (8.9±0.8 and 9.6±0.8 fL, p=0.0001, respectively) and lower than control group (8.9±0.8 and 9.8±0,9 fL, p=0.0001, respectively). There was no correlation both between posttreatment MPV and CCD. Moreover, there were not any relationships between MPV and both prolactin levels before and after the treatment.
Results
According to our findings, serum prolactin levels in prolactinoma before and after the cabergoline treatment were significantly different (128.0±99.7 vs 35.5±39.5 ng/ml, p=0.0001, respectively). Mean cumulative cabergoline dose were calculated as 218.1±252.5 mg. We found that the mean pre-treatment MPV values in prolactinoma group were lower than post-treatment MPV values (8.9±0.8 and 9.6±0.8 fL, p=0.0001, respectively) and lower than control group (8.9±0.8 and 9.8±0,9 fL, p=0.0001, respectively). There was no correlation both between posttreatment MPV and CCD. Moreover, there were not any relationships between MPV and both prolactin levels before and after the treatment.
Conclusions
The cabergoline treatment in prolactinoma may relate high MPV value independent to cumulative cabergoline dose and prolactine levels. On the contrary our finding, Tamm were excluded from the study.
All complete blood count, biochemical and hormonal analysis were performed by automatic analyzer.
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